TABLE 2.
In vivo activities of LCB01-0371 against systemic infection in mice
| Microorganism (inoculum, CFU/mousea) | Antimicrobial agentb | MIC (μg/ml) | ED50, mg/kg (95% confidence limit) |
|---|---|---|---|
| S. aureus giorgio, MSSA | LCB01-0371 | 1 | 4.53 (∼2.26-7.87) |
| (1 × 107) | Linezolid | 2 | 8.05 (∼4.70-13.85) |
| S. aureus p125, MRSA | LCB01-0371 | 1 | 2.96 (∼0.00-5.81) |
| (1 × 108) | Linezolid | 2 | 4.84 (∼0.01-12.66) |
| E. faecalis u810 | LCB01-0371 | 2 | 4.53 (∼2.26-7.87) |
| (2 × 108) | Linezolid | 2 | 5.97 (∼2.23-7.87) |
| S. pneumoniae ATCC 6305 | LCB01-0371 | 0.5 | 2.28 (∼0.00-4.49) |
| (1 × 104) | Linezolid | 1 | 9.10 (∼4.92-23.72) |
| H. influenzae hd2 | LCB01-0371 | 8 | 9.96 (∼4.26-16.75) |
| (7.5 × 108) | Linezolid | 16 | 21.43 (∼9.99-450.60) |
a
Bacterial strains were suspended in 0.9% saline solution containing 5% mucin, except for S. pneumoniae ATCC 6305, which was suspended in 0.9% saline solution.
b
Antimicrobial agents were administered orally at 1 and 4 h postinfection.